NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
67 trialsNCT07435584 2026-02-27
EVER-RECODE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT00081874 2025-04-27
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04339062 2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT06682611 2024-11-12
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2 Not yet recruiting
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02205515 2022-08-19
EBRT
Sunnybrook Health Sciences Centre
Phase 1/2 Completed
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT01034631 2022-07-11
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT01062399 2022-06-09
RTOG 0913
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01784861 2021-07-08
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Phase 1/2 Terminated
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01125293 2021-04-23
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01077986 2021-04-21
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT00560963 2020-12-21
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
Novartis
Phase 1/2 Completed
NCT01075321 2020-10-22
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT00576680 2020-07-09
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00553150 2020-02-13
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01453504 2019-11-08
HD-R3i
University of Cologne
Phase 1/2 Completed
NCT00474929 2019-08-20
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01136733 2019-02-27
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Eisai Inc.
Phase 1/2 Completed
NCT01031446 2018-08-31
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03629847 2018-08-14
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
Phase 1/2 Unknown
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT01259063 2018-03-13
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT01939418 2017-10-03
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea
Phase 1/2 Terminated
NCT01462214 2017-05-10
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00516165 2017-02-07
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 1/2 Completed
NCT00458237 2016-10-20
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00459186 2016-05-16
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01099527 2015-12-29
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Samsung Medical Center
Phase 1/2 Completed
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated